查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968592

Keytruda市场分析及至2035年预测：按类型、产品类型、应用、最终用户、技术、製程、部署类型、功能、阶段及解决方案划分

Keytruda Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Process, Deployment, Functionality, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 417 Pages | 商品交期: 3-5个工作天内

价格
简介目录

Keytruda市场预计将从2024年的282亿美元成长到2034年的702亿美元，复合年增长率约为9.5%。 Keytruda市场涵盖帕博利珠单抗（Pembrolizumab）的分销和开发，帕博利珠单抗是一种免疫疗法药物，透过抑制PD-1路径标靶治疗多种癌症。推动市场成长的因素包括肿瘤适应症的扩大、联合治疗的日益普及以及全球癌症患者群体的不断增长。 Keytruda在提高存活率方面的有效性正在推动市场需求，而持续的研发投入和监管核准将进一步提升市场的潜力。

Keytruda市场正经历强劲成长，这主要得益于其在多种癌症类型中的卓越疗效。肿瘤领域尤为突出，Keytruda在非小细胞肺癌和黑色素瘤等癌症的治疗中展现出优异的疗效。这些细分领域至关重要，因为它们的发生率高，且患者对Keytruda的反应显着。此外，尿路上皮癌和头颈癌领域也因其不断扩展的临床应用和良好的治疗效果而备受关注。免疫疗法领域也呈现显着成长，Keytruda作为查核点抑制剂的功效提升了其市场吸引力。持续的研发投入不断拓展Keytruda的适应症并改善病患疗效，进一步推动了这项成长。此外，Keytruda与其他药物合併使用的联合治疗正成为极具前景的策略，能够产生协同效应并扩大市场潜力。个人化医疗的持续发展进一步巩固了Keytruda的市场地位，使其成为癌症治疗模式中的基石药物。

市场区隔
类型 单株抗体、查核点抑制剂、免疫疗法
产品形式 管瓶、预填充式注射器、冷冻干燥产品、液体
适应症 肿瘤学、非小细胞肺癌、恶性黑色素瘤、头颈癌、肾细胞癌、何杰金氏淋巴瘤、尿路上皮癌、胃癌、子宫颈癌
最终用户 医院、诊所、癌症治疗中心和研究机构
科技 生物技术、重组DNA技术、单株抗体生产
过程 生产製造、分销、品管和法规遵从
部署 住院、门诊病人和居家照护
功能 治疗性、预防性、安宁疗护性
步 临床试验、上市后监测及商业化
解决方案 患者援助计划、数位健康解决方案

市场概况：

凭藉其卓越的疗效和不断扩大的适应症，Keytruda 已占据免疫疗法市场的重要份额。我们与价值提案相符的定价策略，巩固了我们的竞争优势。近期推出的新产品，凭藉着创新配方和扩展的治疗适应症，进一步增强了我们的市场地位。这些策略倡议巩固了 Keytruda 在不断变化的市场动态中的市场地位。儘管竞争基准分析清楚展现了 Keytruda 的优越性，但Opdivo和TECENTRIQ等竞争对手也构成了严峻的挑战。监管环境，尤其是在美国和欧洲，正影响市场趋势，其严格的核准流程和报销政策令人担忧。市场的特点是积极的研发投入，这促进了创新并推动了市场发展。 Keytruda 的未来成长得益于正在进行的临床试验和策略合作，确保了我们在竞争激烈的市场环境中保持韧性。

主要趋势和驱动因素：

受癌症免疫疗法进展和癌症发病率上升的推动，Keytruda市场正经历强劲成长。一个关键趋势是Keytruda在联合治疗中的应用日益广泛，从而提高了治疗效果并扩大了临床应用范围。持续的研究和临床试验正在探索Keytruda与其他免疫肿瘤药物和标靶治疗的新型联合疗法，进一步支持了这一趋势。另一个关键驱动因素是Keytruda核准用于治疗多种癌症，包括黑色素瘤、肺癌和膀胱癌。这些核准正在推动市场扩张，并扩大患者获得这种创新疗法的机会。此外，对个人化医疗的日益重视正在加速开发以生物标记主导的方法，以优化Keytruda的治疗潜力。製药公司之间的策略联盟和伙伴关係也对市场产生影响，这些联盟和合作旨在加强其药物开发平臺和商业性覆盖范围。在尚未开发的市场，尤其是在医疗基础设施不断改进、人们对先进癌症疗法的认知不断提高的发展中地区，新的机会正在涌现。这些趋势使Keytruda市场处于持续成长和创新的有利地位。

限制与挑战：

Keytruda市场目前面临许多重大限制与挑战。首要障碍是治疗费用高昂，不仅限制了许多病患的用药，也加重了医疗预算的负担。此外，免疫疗法药物复杂的法规环境也减缓了市场准入和扩张速度，阻碍了市场成长。另一个挑战是竞争疗法的出现，这可能会侵蚀Keytruda的市占率并影响其盈利。此外，个人化治疗方法的需求也增加了治疗标准化的难度，加重了医疗服务提供者的负担。最后，患者对免疫疗法的反应存在个别差异，因此需要持续进行研发，这在时间和成本方面都可能造成沉重的负担。总而言之，这些因素构成了Keytruda市场必须克服的障碍，才能维持其成长动能。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 查核点抑制剂
    • 免疫治疗药物
  • 市场规模及预测：依产品划分
    • 管瓶
    • 预填充式注射器
    • 冷冻干燥
    • 液体溶液
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 非小细胞肺癌
    • 黑色素瘤
    • 头颈癌
    • 肾臟细胞癌
    • 何杰金氏淋巴瘤
    • 尿路上皮癌
    • 胃癌
    • 子宫颈癌
  • 市场规模及预测：依最终用户划分
    • 医院
    • 医疗
    • 癌症治疗中心
    • 研究所
  • 市场规模及预测：依技术划分
    • 生物技术
    • 重组DNA技术
    • 单株抗体生产
  • 市场规模及预测：依製程划分
    • 製造业
    • 分配
    • 品管
    • 监理合规
  • 市场规模及预测：依发展状况
    • 住院病人
    • 门诊治疗
    • 居家医疗
  • 市场规模及预测：依功能划分
    • 按治疗区域
    • 预防性药物
    • 安宁疗护
  • 市场规模及预测：依阶段划分
    • 临床试验
    • 上市后监测
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 患者援助计划
    • 数位健康解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Seagen
  • BeiGene
  • MacroGenics
  • Innovent Biologics
  • Zymeworks
  • Arcus Biosciences
  • CStone Pharmaceuticals
  • I-Mab Biopharma
  • Junshi Biosciences
  • Harbour BioMed
  • Hutchmed
  • Kura Oncology
  • Compugen
  • Immunocore
  • OncoSec Medical
  • Agenus
  • F-star Therapeutics
  • Pieris Pharmaceuticals
  • Apexigen
  • Oncologie

第九章：关于我们

简介目录
Product Code: GIS33155

Keytruda Market is anticipated to expand from $28.2 billion in 2024 to $70.2 billion by 2034, growing at a CAGR of approximately 9.5%. The Keytruda Market encompasses the distribution and development of pembrolizumab, an immunotherapy drug targeting various cancers by inhibiting the PD-1 pathway. This market is driven by its expanding indications across oncology, growing adoption in combination therapies, and increasing prevalence of cancer globally. Keytruda's efficacy in improving survival rates fuels demand, while ongoing research and regulatory approvals further enhance its market potential.

The Keytruda market is experiencing robust growth, propelled by its efficacy in treating various cancer types. The oncology segment is at the forefront, with non-small cell lung cancer and melanoma treatments demonstrating superior performance. These sub-segments are crucial due to their high prevalence and the significant patient response to Keytruda. Following closely, the urothelial carcinoma and head and neck cancer sub-segments are gaining traction, driven by expanding clinical applications and positive therapeutic outcomes. The immunotherapy segment is also witnessing substantial growth, with Keytruda's role as a checkpoint inhibitor enhancing its appeal. This growth is underscored by ongoing research and development efforts, which are broadening its indications and improving patient outcomes. Additionally, the combination therapy approach, integrating Keytruda with other agents, is emerging as a promising strategy, offering synergistic benefits and extending its market potential. The continuous evolution of personalized medicine further augments Keytruda's market trajectory, positioning it as a cornerstone in cancer treatment paradigms.

Market Segmentation
TypeMonoclonal Antibodies, Checkpoint Inhibitors, Immunotherapy Agents
ProductVials, Pre-filled Syringes, Lyophilized, Liquid Solutions
ApplicationOncology, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Renal Cell Carcinoma, Hodgkin Lymphoma, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer
End UserHospitals, Clinics, Cancer Treatment Centers, Research Institutes
TechnologyBiotechnology, Recombinant DNA Technology, Monoclonal Antibody Production
ProcessManufacturing, Distribution, Quality Control, Regulatory Compliance
DeploymentInpatient, Outpatient, Homecare
FunctionalityTherapeutic, Prophylactic, Palliative
StageClinical Trials, Post-Market Surveillance, Commercialization
SolutionsPatient Support Programs, Digital Health Solutions

Market Snapshot:

Keytruda commands a significant share in the immunotherapy market, driven by its efficacy and expanding indications. Its pricing strategy aligns with its value proposition, maintaining competitive positioning. Recent product launches have reinforced its market presence, leveraging innovative formulations and expanded therapeutic applications. These strategic initiatives have bolstered Keytruda's standing amidst evolving market dynamics. Competitive benchmarking reveals Keytruda's dominance, yet rivals like Opdivo and Tecentriq present formidable challenges. Regulatory landscapes, particularly in the U.S. and Europe, influence market trajectories with stringent approval processes and reimbursement policies. The market is characterized by robust R&D investment, fostering innovation and driving market evolution. Keytruda's future growth is supported by ongoing clinical trials and strategic partnerships, ensuring its resilience in a competitive landscape.

Geographical Overview:

The Keytruda market is witnessing substantial growth across diverse regions, each presenting unique opportunities. North America remains a dominant player due to its advanced healthcare infrastructure and extensive research initiatives. The region's focus on innovative cancer therapies bolsters Keytruda's market presence. Europe follows, with robust healthcare systems and increased government support for immunotherapy treatments driving demand. In Asia Pacific, rapid urbanization and rising cancer incidences are propelling market expansion. Countries like China and India are emerging as significant growth pockets, with increasing healthcare investments and improved access to treatments. Latin America shows promise, with Brazil and Mexico leading the charge in adopting advanced cancer therapies. The Middle East & Africa are also gaining traction, recognizing the potential of immunotherapy in addressing unmet medical needs. The region's growing healthcare awareness and infrastructure development present lucrative opportunities for Keytruda's market penetration. These emerging markets are crucial for sustaining global Keytruda demand.

Key Trends and Drivers:

The Keytruda market is experiencing robust growth propelled by advancements in cancer immunotherapy and rising cancer prevalence. A major trend is the increasing adoption of Keytruda in combination therapies, enhancing treatment efficacy and broadening its clinical applications. This trend is supported by ongoing research and clinical trials exploring novel combinations with other immuno-oncology agents and targeted therapies. Another significant driver is the expanding approvals for Keytruda across various cancer types, including melanoma, lung, and bladder cancer. These approvals are fueling market expansion and increasing patient access to innovative treatments. Additionally, the growing focus on personalized medicine is accelerating the development of biomarker-driven approaches, optimizing Keytruda's therapeutic potential. The market is further influenced by strategic collaborations and partnerships among pharmaceutical companies, aiming to enhance drug development pipelines and commercial reach. Opportunities are emerging in untapped markets, particularly in developing regions, where healthcare infrastructure is improving, and awareness of advanced cancer therapies is rising. These dynamics position the Keytruda market for sustained growth and innovation.

Restraints and Challenges:

The Keytruda market is currently encountering several significant restraints and challenges. A primary obstacle is the high cost of treatment, which limits accessibility for many patients and strains healthcare budgets. Additionally, the complex regulatory environment surrounding immunotherapy drugs can delay market entry and expansion, creating barriers for growth. Another challenge is the emergence of competitive therapies, which could potentially erode Keytruda's market share and impact profitability. Furthermore, the need for personalized treatment regimens complicates the standardization of care, increasing the burden on healthcare providers. Lastly, the variability in patient response to immunotherapy necessitates ongoing research and development, which can be both time-consuming and costly. These factors collectively present hurdles that the Keytruda market must navigate to sustain its trajectory.

Key Players:

Seagen, BeiGene, MacroGenics, Innovent Biologics, Zymeworks, Arcus Biosciences, CStone Pharmaceuticals, I-Mab Biopharma, Junshi Biosciences, Harbour BioMed, Hutchmed, Kura Oncology, Compugen, Immunocore, OncoSec Medical, Agenus, F-star Therapeutics, Pieris Pharmaceuticals, Apexigen, Oncologie

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Checkpoint Inhibitors
    • 4.1.3 Immunotherapy Agents
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Vials
    • 4.2.2 Pre-filled Syringes
    • 4.2.3 Lyophilized
    • 4.2.4 Liquid Solutions
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Non-Small Cell Lung Cancer
    • 4.3.3 Melanoma
    • 4.3.4 Head and Neck Cancer
    • 4.3.5 Renal Cell Carcinoma
    • 4.3.6 Hodgkin Lymphoma
    • 4.3.7 Urothelial Carcinoma
    • 4.3.8 Gastric Cancer
    • 4.3.9 Cervical Cancer
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Cancer Treatment Centers
    • 4.4.4 Research Institutes
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Recombinant DNA Technology
    • 4.5.3 Monoclonal Antibody Production
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Manufacturing
    • 4.6.2 Distribution
    • 4.6.3 Quality Control
    • 4.6.4 Regulatory Compliance
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Inpatient
    • 4.7.2 Outpatient
    • 4.7.3 Homecare
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Therapeutic
    • 4.8.2 Prophylactic
    • 4.8.3 Palliative
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Clinical Trials
    • 4.9.2 Post-Market Surveillance
    • 4.9.3 Commercialization
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Patient Support Programs
    • 4.10.2 Digital Health Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Functionality
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Functionality
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Functionality
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Functionality
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Functionality
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Functionality
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Functionality
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Functionality
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Functionality
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Functionality
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Functionality
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Functionality
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Functionality
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Functionality
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Functionality
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Functionality
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Functionality
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Functionality
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Functionality
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Functionality
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Functionality
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Functionality
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Functionality
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Functionality
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Seagen
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BeiGene
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 MacroGenics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Innovent Biologics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Zymeworks
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Arcus Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 CStone Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 I-Mab Biopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Junshi Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Harbour BioMed
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Hutchmed
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Kura Oncology
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Compugen
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Immunocore
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 OncoSec Medical
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Agenus
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 F-star Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Pieris Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Apexigen
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Oncologie
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us